Ming Ming Zhu
Shanghai Jiao Tong University
14 Papers
55 Citations
Ming Ming Zhu is an academic researcher from Shanghai Jiao Tong University. The author has contributed to research in topics: Colorectal cancer & Medicine. The author has an hindex of 11, co-authored 14 publications. Previous affiliations of Ming Ming Zhu include Sichuan University.
Chat about Author
Papers
MicroRNA expression profiling identifies miR-328 regulates cancer stem cell-like SP cells in colorectal cancer
TL;DR: MiR-328 has an important role in maintaining cancer stem-like SP phenotype that may be a potential target for effective CRC therapy and is identified as a potential stemness miRNA of SP phenotype.
Predictive and prognostic roles of BRAF mutation in patients with metastatic colorectal cancer treated with anti-epidermal growth factor receptor monoclonal antibodies: a meta-analysis.
TL;DR: This study aimed to evaluate the predictive and prognostic roles of BRAF mutation in patients with metastatic colorectal cancer treated with anti‐epidermal growth factor receptor (EGFR) monoclonal antibodies (MoAbs).
44
•Journal Article
Helicobacter pylori regulates TLR4 and TLR9 during gastric carcinogenesis.
TL;DR: In superficial gastritis and atrophy/intestinal metaplasia the inflammation was predominately mediated by TLR4, while in gastric cancer the inflammation wasn't as high as in other groups and was mainly mediated byTLR9.
36
High suppressor of cytokine signaling-3 expression impairs STAT3-dependent protective effects of interleukin-22 in ulcerative colitis in remission.
An Tao Xu,Yi Li,Di Zhao,Jun Shen,Xi Tao Xu,Yu Qi Qiao,Ming Ming Zhu,Tian Rong Wang,Yun Cui,Luo Yan Ai,Zhi Hua Ran +10 more
TL;DR: SOCS3 overexpression impairs IL-22–mediated epithelial homeostasis and mucosal wound healing, which could be the mechanism for high SOCS3 IEC expression contributed early relapse of mucosal inflammation.
29
Meta-analysis: the efficacy and safety of monoclonal antibody targeted to epidermal growth factor receptor in the treatment of patients with metastatic colorectal cancer.
TL;DR: To evaluate systematically the efficacy and safety of anti‐epidermal growth factor receptor (EGFR) monoclonal antibody added to a chemotherapeutic regimen in the treatment of patients with metastatic colorectal cancer.
16